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induction of attaching and effacing to the establishment of
persistent infections in animals (4, 18).
Several lines of evidence support the hypothesis that Stx
can suppress the bovine immune response. Stx1 targets bovine peripheral blood (23, 25, 31) and intraepithelial lymphocytes (IEL) (22) in vitro. Stx1 binds to Stx receptorexpressing (Gb3-/CD77-positive) lymphocytes at early
activation stages (31) and blocks the proliferation of distinct
lymphocyte subpopulations (CD8␣⫹ T cells, B cells) in vitro
(25). A significant portion of bovine CD8␣⫹ IEL expresses
Stx-receptors in situ (22). Inoculation of ligated ileal loops
in 2-week-old calves with Stx1-producing STEC reduces the
number of CD8␣⫹ IEL within 12 h (24). Direct evidence for
a suppression of immune cell functions in the course of
STEC infections in cattle, as observed during experimental
STEC infections in pigs (5), has been lacking. Although
bovine lymphocytes are sensitive to minute concentrations
of Stx1 and Stx2 (1, 12, 13, 25), Stxs do not completely
abolish the development of specific immune responses in
naturally and experimentally infected cattle. Antibodies
against O157 lipopolysaccharide (LPS), Stx1, and Stx2 are
frequently detected in bovine sera and mucosal secretions
(colostra) (17, 28). Since Stx1 suppresses bovine lymphocytes in vitro without inducing cell death (25), we hypothesized that in vivo, Stxs primarily reduce or delay the host’s
cellular immune response, thereby generating an opportunity for STEC bacterial colonization. The objectives of the
present study were to monitor the levels and durations of
fecal shedding of Stx-producing (Stx⫹) and Stx-negative
(Stx⫺) E. coli and to examine specific cellular and humoral
immune responses in calves experimentally inoculated with
either human pathogenic Stx2⫹ or Stx⫺ E. coli O157:H7
bacteria.

Enterohemorrhagic Escherichia coli (EHEC) is a common
cause of hemorrhagic colitis (HC) in very young, elderly,
and immunocompromised humans (16, 30). In the United
States, the EHEC serotype most often associated with bloody
diarrhea is O157:H7, but non-O157 EHEC serotypes have
caused significant outbreaks in the United States and abroad
(30, 35). Up to 10% of patients with EHEC-associated HC
develop hemolytic uremic syndrome, with resulting renal and
neurological damage and, occasionally, death (21). All EHEC
strains produce one or more cytotoxins called Shiga toxins
(Stx1 and Stx2) (27), which target endothelial cells, are believed to mediate much of the tissue damage during HC and
hemolytic uremic syndrome (29, 37), and can influence the
duration of Stx-producing E. coli (STEC) shedding by ruminants (7).
Ruminants are important sources of EHEC O157:H7 strains
because they frequently shed STEC in their feces (26). Single
STEC O157:H7 clones can be repeatedly isolated from a herd
(6, 14), implying that these clones persist within that herd. This
could result from frequent transmission between and reinfection of different animals (2) or from a true persistence in single
animals (3, 7, 8). Experimental infections of calves revealed
that several bacterial factors involved in the “attaching and
effacing” adherence of E. coli O157:H7 to epithelial cells (e.g.,
intimin [10], other products of the locus of enterocyte effacement [11], and efa-1 [32]) promote bacterial colonization of the
intestinal mucosa. However, recent studies failed to link the
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Although cattle develop humoral immune responses to Shiga-toxigenic (Stxⴙ) Escherichia coli O157:H7,
infections often result in long-term shedding of these human pathogenic bacteria. The objective of this study
was to compare humoral and cellular immune responses to Stxⴙ and Stxⴚ E. coli O157:H7. Three groups of
calves were inoculated intrarumenally, twice in a 3-week interval, with different strains of E. coli: a Stx2producing E. coli O157:H7 strain (Stx2ⴙO157), a Shiga toxin-negative E. coli O157:H7 strain (StxⴚO157), or
a nonpathogenic E. coli strain (control). Fecal shedding of Stx2ⴙO157 was significantly higher than that of
StxⴚO157 or the control. Three weeks after the second inoculation, all calves were challenged with Stx2ⴙO157.
Following the challenge, levels of fecal shedding of Stx2ⴙO157 were similar in all three groups. Both groups
inoculated with an O157 strain developed antibodies to O157 LPS. Calves initially inoculated with StxⴚO157,
but not those inoculated with Stx2ⴙO157, developed statistically significant lymphoproliferative responses to
heat-killed Stx2ⴙO157. These results provide evidence that infections with STEC can suppress the development of specific cellular immune responses in cattle, a finding that will need to be addressed in designing
vaccines against E. coli O157:H7 infections in cattle.
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MATERIALS AND METHODS
Animals. Holstein calves 6 to 8 weeks old were purchased from local sources.
Calves were allowed to acclimate to the diet and conditions at the National
Animal Disease Center (NADC) for 3 weeks prior to oral inoculations. During
infections, the calves were housed in BL2 containment barns and fed a diet of
two-thirds grain and one-third hay. Animal care was in accordance with requirements of the NADC Animal Care and Use Committee and the Association for
Assessment and Accreditation of Laboratory Animal Care. Calves were euthanized with sodium pentobarbital at the end of the study.
Inoculations. The strains used in this study were EHEC O157:H7 strain 86-24,
a streptomycin-resistant mutant of an Stx2-producing strain isolated from an
outbreak in Washington state (36); E. coli O157:H7 strain 87-23, a nalidixicresistant mutant of a strain isolated from the same outbreak as 86-24 and lacking
both Stx1 and Stx2 genes (19, 36); and, as a control strain, a nalidixic acidresistant mutant of E. coli strain 123 (O43:H28), a porcine isolate which does not
produce Stx and is not pathogenic in cattle (9). Escherichia coli cultures were
prepared and stored at ⫺80°C as previously described (9).
Calves (five calves/group) were inoculated intrarumenally, on day 0 and day 21,
with approximately 1010 CFU of strain 86-24 (Stx2⫹O157), 87-23 (Stx⫺O157), or
123 (control) bacteria in 100 ml of trypticase soy broth (Becton Dickinson,
Cockeysville, MD) as previously described (11, 33). Three weeks after the second
inoculation (day 42), all calves were similarly inoculated with Stx2⫹O157. This
third inoculation of all calves with the same Stx⫹O157 strain is referred to as the
“challenge” to clearly differentiate it from the two initial inoculations of calves in
different groups with different strains.
Bacteriology. Freshly isolated fecal samples (approximately 2 g) were diluted
1:10 and serially diluted in sterile phosphate-buffered saline. Sorbitol-negative
STEC O157:H7 bacteria were quantitated on sorbitol-MacConkey agar (Oxoid,
Basingstoke, United Kingdom) supplemented with streptomycin (200 g per ml)
or nalidixic acid (20 g per ml) to select for strains 86-24 or 87-23, respectively.
Randomly selected antibiotic-resistant, sorbitol-negative colonies were tested for
O157 LPS antigen by slide agglutination (Oxoid). E. coli strain 123 bacteria were
quantitated on MacConkey agar (Becton Dickinson, Cockeysville, MD) containing 20 g per ml of nalidixic acid. Enrichment cultures were performed by adding
up to 10 g of feces to trypticase soy broth containing 0.01% bile salts 3 (Difco,
Detroit, MI) to a final volume of 100 ml. These cultures were incubated overnight, without shaking, at 37°C. Samples (100 l) from enrichment cultures of
feces that were negative by direct plating were incubated on sorbitol-MacConkey
agar with the appropriate antibiotic. Enrichment plates were scored as either
positive or negative and were not quantitated. Positive enrichment cultures were
arbitrarily assigned a value of 10 CFU g⫺1, and those which were negative were
given a value of 1 CFU/g. Student’s t test was used to determine statistical
significance.
Detection of plasma antibodies to O157 LPS and Stx2. Titers against O157
LPS were determined by a blocking enzyme-linked immunosorbent assay (20),
using monoclonal antibody MARC 13B3 (38) and highly purified LPS from E.
coli O157:H7 (strain CDC EDL 933). MARC 13B3 lacks cross-reactivity with

other bacteria, such as Brucella spp. and Yersinia enterocolitica, a problem often
found with polyclonal antisera against O157. Endpoints were defined using
receiver-operator-characteristic analysis of 1:4 dilutions of known positive and
negative serum samples (20).
Vero cell cytotoxicity neutralization assays were performed as previously described (15). Briefly, dilutions of plasma were added to samples containing Stx2.
After incubation for 1 h at 37°C, the plasma-toxin mixtures were added to Vero
cells and incubated at 37°C for 48 h. The cells were then stained for viability with
trypan blue. Antisera obtained from four calves hyperimmunized by subcutaneous injections with 100 g of a noncytotoxic amino acid substitution mutant of
Stx2e (15) were pooled and used as a positive anti-Stx control serum. Antibodies
against Stx2e cross-reacted with and neutralized Stx2 in our system.
Preparation of antigen for peripheral blood mononuclear cell (PBMC) stimulation. Heat-killed Stx2⫹ E. coli O157:H7 bacteria (HK-O157) were used for in
vitro stimulation. One milliliter containing 1010 CFU of E. coli O157:H7 strain
86-24 (harvested from a fresh overnight culture) was boiled for 15 min. The cells
were pelleted by centrifugation and resuspended in 1 ml of complete media
(RPMI; 25 mM HEPES and L-glutamine [Gibco, Carlsbad, CA], 10% fetal calf
serum, and 50 g gentamicin per ml [Sigma, St. Louis, MO]). Aliquots of the
cells were tested for sterility by plating them on trypticase soy agar plates and
stored at ⫺80°C until needed.
PBMC stimulation. PBMCs were isolated from whole blood collected at
weekly intervals. The blood was centrifuged for 25 min at 1,170 ⫻ g. Plasma
samples were removed and stored at ⫺80°C for further analysis. Buffy coat cells
were subjected to two rounds of hypotonic red blood cell lysis. PBMCs were then
isolated by Percoll (Pharmacia, Piscataway, NJ) density gradient (P ⫽ 1.08)
centrifugation at 450 ⫻ g for 40 min. Cells were washed twice in complete media.
Cells were then diluted to 6.6 ⫻ 106 cells per ml and aliquoted into 96-well plates
at 150 l of cells (106 cells) per well. Stimulants (HK-O157, equivalent to 5 ⫻ 104
CFU E. coli O157:H7 cells, or 1 g per ml ConA), 50 l per well, were added to
each well. Plates were incubated for 72 h in 5% CO2 at 39°C. PBMCs were then
pulsed with media containing 50 Ci of [3H]thymidine and incubated for an
additional 18 h. Cells were harvested with a Harvester 96 (Tomtech, Orange,
CN) and analyzed using a 1450 Microbeta Plus scintillation counter (Wallac,
Gaithersberg, MD). The stimulation index (SI) is the mean for three wells of
cells incubated with stimulant divided by the mean for three wells incubated with
media alone. Cell preparations in which the SI for ConA was less than 10 times
that for cells incubated with media alone were considered poor and were excluded from further analysis. Statistical analysis was performed using the SAS
software package and the analysis of variance technique.

RESULTS
All of the calves remained healthy throughout the study.
None of the calves shed detectable levels of E. coli O157:H7
prior to the first inoculation. Only one of the calves in the
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FIG. 1. Fecal shedding of E. coli by calves inoculated with different strains. Numbers of inoculum bacteria recovered from feces of calves
inoculated with Stx2⫹ E. coli O157:H7 strain 86-24 (Stx2⫹), Stx⫺ E. coli O157:H7 strain 87-23 (Stx⫺), or control E. coli O43:H28 strain 123
(Control) are shown. Samples which were negative by direct culturing methods (⬍100 CFU g⫺1) were tested by enrichment culturing. All values
below the dashed line represent enrichment levels. Samples which were positive by enrichment analysis were given an arbitrary value of 10 CFU
g⫺1, and those which were negative were given a value of 1 CFU/g. Arrows indicate dates of inoculation. Data are presented as mean numbers
(⫾ standard errors of the means) of CFU g⫺1 for the indicated groups.
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study (one calf in the negative-control group) had detectable antibodies against O157 LPS prior to the first inoculation.
The inoculum strain was recovered in higher numbers and
for a longer time from calves initially inoculated with Stx2⫹
O157:H7 strain 86-24 than from calves inoculated with either
of the other two E. coli strains (Fig. 1). More than 102 CFU of
Stx2⫹O157 bacteria/g of feces were recovered for 9 and 14 days
after the first and second inoculations, respectively. Fecal shedding of Stx⫺O157 decreased at a rate similar to that of the
control bacteria, with both strains at ⬍102 CFU g⫺1 of feces by
the fifth day after each inoculation. The differences in fecal
shedding between the Stx2⫹ and Stx⫺O157 strains were statistically significant (P ⬍ 0.05 by Student’s t test) between days 2
and 13 after the first inoculation and days 22 and 27 after the
second inoculation.

The fecal shedding of Stx2⫹O157 bacteria was similar in all of
the calves after they were challenged with Stx2⫹O157 during
week 7 (3 weeks after their second inoculation with Stx2⫹O157,
Stx⫺O157, or control E. coli bacteria) (Fig. 2). Thus, prior exposure to high doses of STEC O157:H7 strain 86-24, Stx⫺ E. coli
O157:H7 strain 87-23, or control strain 123 did not reduce the
duration or extent of fecal shedding of STEC O157:H7 bacteria
after the challenge.
Following the initial two inoculations, all calves inoculated
with either Stx2⫹O157 or Stx⫺O157 developed antibodies to
the O antigen of E. coli O157:H7 (Fig. 3). The rates of seroconversion were similar in both groups. Three of the calves
inoculated with control bacteria had low titers (ⱕ16) of antiO157 LPS, and the highest titer in this group was seen at week
4 in the calf which had serum antibodies to LPS O157 prior to
the first inoculation. Calves in all three groups developed antibodies to O157 LPS following challenge with Stx2⫹O157
(Fig. 3). None of the calves in any of the three groups developed antibodies against Stx2.
The in vitro PBMC proliferation assay was used to monitor the lymphoproliferative responses of infected calves to
HK-O157 antigens (Fig. 4). Four of the five calves initially
inoculated with Stx⫺O157 developed a high proliferative
immune response to HK-O157. This response became apparent at week 3 and reached its strongest level after the
challenge. Three of the five calves in this group had SIs
greater than 10 for 2 or more weeks. In contrast, calves
initially inoculated with either Stx2⫹O157 or control bacteria did not develop consistent PBMC proliferative responses
to HK-O157 at any point during the study. Two of the five
calves inoculated with Stx2⫹O157, and one of the five inoculated with control bacteria, had SIs of ⬎10 in a single assay
(at week 4 or 8 for Stx2⫹O157 calves and at week 10 for the
control calf). Trend analysis using the sum of squares technique showed that the cumulative PBMC proliferative response for the calves inoculated with the Stx⫺ strain was
significantly higher than that for the calves which received
Stx2⫹O157 (P ⫽ 0.0001) or control bacteria (P ⫽ 0.0009).
There were no consistent differences in overall ConA activation (Fig. 4).

FIG. 3. Development of antibody titers against O157 LPS in calves inoculated with different E. coli strains. Data are shown as the means (⫾
standard errors of the means) of log2 titers of plasma antibodies. For the designations of calf groups, see the legend to Fig. 1. Arrows indicate the
dates of the initial inoculations (small arrows) and challenge (large arrow).
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FIG. 2. Fecal shedding of the challenge strain by three groups of
calves which were challenged with Stx2⫹ O157:H7 strain 86-24 following prior inoculations with different strains of E. coli. The arrow indicates the date of the challenge. Data are presented as mean numbers
(⫾ standard errors of the means) of CFU g⫺1 of sorbitol-negative Strr
O157:H7 bacteria in the feces of the indicated groups. Group designations are same as those in the legend to Fig. 1.
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DISCUSSION
This study provides the first evidence that STEC infections
can suppress the development of an antigen-specific cellular
immune response in cattle. Following the initial inoculations,
calves inoculated with Stx2⫹ E. coli O157:H7 strain 86-24 shed
the inoculum strain at higher levels and for longer periods than
did calves inoculated with Stx⫺O157:H7 strain 87-23. Despite
this increased colonization, the lymphoproliferative responses
to HK-O157 in calves inoculated with Stx2⫹O157 were significantly lower than the responses in calves inoculated with
Stx⫺O157 and were similar to the responses in calves that
received control bacteria. This reduced cellular immune response in Stx2⫹O157-inoculated calves extends evidence that
STEC possesses virulence traits that actively suppress cellular
elements of the host immune response (1, 22, 23, 32). The
differences observed in the lymphoproliferative responses in
calves inoculated with the Stx2⫹O157 and Stx⫺O157 strains
used in this study are consistent with the suppressive effects of
Stxs on bovine peripheral and intraepithelial lymphocytes observed in vitro and in vivo (1, 12, 13, 22–25, 31).
Our studies were not designed to examine the mechanism
underlying the observed immunosuppression. However, the
observation that the PBMCs obtained from the different inoculation groups did not significantly differ in their proliferative
responses to ConA provides preliminary evidence that the
effect of STEC infection on the bovine immune system was not
generalized. Furthermore, the observed immunosuppressive
effects of STEC infections were restricted to antigen-specific in
vitro PBMC proliferative responses. This contrasts with a generalized suppression of T cells described for mice and piglets,
which is characterized by a drop in the reactivities of lymphocytes to ConA following injection with purified Stx2 and inoc-

ulation with Stx1⫹ E. coli strain O111:NM, respectively (5, 34).
Differences in levels of systemic Stx may be responsible for the
observed differences in the effects of Stx on the immune system
in the different studies. The mouse and piglet studies were
more likely to involve high systemic concentrations of Stx.
Mice were intravenously injected and piglets were orally inoculated with high doses of Stx⫹ bacteria at 24 h of age, when gut
closure may not have been complete and the likelihood of
toxin absorption from the intestine was increased. Consequently, the effects of Stx on the immune system in these
models may have been high enough to affect “general” functions, like mitogenic responsiveness. The effects of Stx in calves
infected at 6 to 8 weeks of age (notwithstanding the high
inoculum doses) may better reflect the effects of “physiologic”
infections that occur in the field.
Thus, we interpret the present findings as support for our
hypothesis that Stxs are immunosuppressive factors which play
a role in promoting STEC colonization in the bovine host
primarily by reducing or delaying the host’s antigen-specific
cellular immune response against the bacteria.
As previously postulated (31), the immunosuppressive effects of STEC infections appeared to result from a prevention
of the onset of an immune response rather than the downregulation of an established one. The development of an in vitro
PBMC response was prevented when Stx2 was present at the
time that the naı̈ve O157:H7 E. coli-specific immune cells were
first stimulated by the initial inoculations (i.e., in calves initially
inoculated with Stx2⫹O157). In contrast, the Stx2⫹O157 strain
did not exert an immunosuppressive effect after the immune
response was efficiently induced by two inoculations with
Stx⫺O157. Calves initially inoculated with Stx⫺O157 showed a
continued proliferative response that, similar to an anamnestic
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FIG. 4. Comparison over time of the lymphoproliferative responses to heat-killed Stx2⫹ E. coli O157:H7 bacteria (HK-O157) in calves
inoculated with different E. coli strains. Calves were inoculated twice (on days 0 and 21) with Stx2⫹ E. coli O157:H7 strain 86-24 (Stx2⫹),
non-Shiga-toxigenic E. coli O157:H7 strain 87-23 (Stx⫺), or control E. coli O43:H28 strain 123 (Control) prior to a final challenge (at 7 weeks
postinoculation) with Stx2⫹ E. coli O157:H7 strain 86-24. Results are shown as the means (⫾ standard errors of the means) of the SIs obtained
with PBMCs from five calves per group. The index for an individual animal was determined by dividing the mean counts per minute for three wells
stimulated with HK-O157 by the mean counts per minute for three wells of nonstimulated cells. Lymphoproliferative responses to ConA
stimulation are shown in the insert. Data obtained with blood samples during weeks 1, 2, and 3, during weeks 4 and 6, and postchallenge (during
weeks 7, 8 and 10) were combined within those respective groups.
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